Literature DB >> 22908174

Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty.

Ivor Byren1, Shruta Rege, Ed Campanaro, Sara Yankelev, Diane Anastasiou, Gennady Kuropatkin, Richard Evans.   

Abstract

The prevalence of Staphylococcus aureus causing prosthetic joint infection (PJI) supports investigation of higher doses of daptomycin in the management of PJI. This was a prospective, randomized controlled trial studying safety and efficacy of daptomycin (6 and 8 mg/kg of body weight) compared with standard-of-care therapy for PJI. This open-label study randomized 75 patients undergoing 2-stage revision arthroplasty to daptomycin at 6 or 8 mg/kg or a comparator (vancomycin, teicoplanin, or semisynthetic penicillin). After prosthesis removal, patients received 6 weeks of antibiotic treatment and a 2- to 6-week antibiotic-free period before implantation of a new prosthesis. Test of cure (TOC) was within 1 to 2 weeks after reimplantation. The primary objective was evaluation of creatine phosphokinase (CPK) levels. Secondary objectives were clinical efficacy and microbiological assessments. Of 73 CPK safety population patients, CPK elevation of >500 U/liter occurred in 4 of 25 (16.0%) (daptomycin, 6 mg/kg) and 5 of 23 (21.7%) (daptomycin, 8 mg/kg) daptomycin-treated patients and 2 of 25 (8.0%) comparator patients. Adverse-event rates were similar among daptomycin and comparator groups. Among modified intent-to-treat patients at TOC, clinical success rates were 14 of 24 (58.3%) for 6 mg/kg daptomycin, 14 of 23 (60.9%) for 8 mg/kg daptomycin, and 8 of 21 (38.1%) for the comparator. Overall microbiological success at TOC was 12 of 24 (50.0%) for 6 mg/kg daptomycin, 12 of 23 (52.2%) for 8 mg/kg daptomycin, and 8 of 21 (38.1%) for comparator patients. In conclusion, daptomycin at 6 and 8 mg/kg given for up to 6 weeks was safe and appeared to be effective in managing staphylococcal PJI using a 2-stage revision arthroplasty technique in a total of 49 patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22908174      PMCID: PMC3486533          DOI: 10.1128/AAC.00038-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Treatment of infections associated with surgical implants.

Authors:  Rabih O Darouiche
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 2.  Prosthetic joint infections.

Authors:  Irene G Sia; Elie F Berbari; Adolf W Karchmer
Journal:  Infect Dis Clin North Am       Date:  2005-12       Impact factor: 5.982

Review 3.  Prosthetic-joint infections.

Authors:  Werner Zimmerli; Andrej Trampuz; Peter E Ochsner
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 4.  Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?

Authors:  Luca Lazzarini; Benjamin A Lipsky; Jon T Mader
Journal:  Int J Infect Dis       Date:  2005-05       Impact factor: 3.623

Review 5.  New developments in diagnosis and treatment of infection in orthopedic implants.

Authors:  A F Widmer
Journal:  Clin Infect Dis       Date:  2001-09-01       Impact factor: 9.079

6.  Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  J T Mader; K Adams
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Risk factors for prosthetic joint infection: case-control study.

Authors:  E F Berbari; A D Hanssen; M C Duffy; J M Steckelberg; D M Ilstrup; W S Harmsen; D R Osmon
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

Review 8.  Osteomyelitis.

Authors:  Daniel P Lew; Francis A Waldvogel
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 9.  NIH consensus conference: Total hip replacement. NIH Consensus Development Panel on Total Hip Replacement.

Authors: 
Journal:  JAMA       Date:  1995-06-28       Impact factor: 56.272

10.  Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology.

Authors:  P Bejon; A Berendt; B L Atkins; N Green; H Parry; S Masters; P McLardy-Smith; R Gundle; I Byren
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

View more
  31 in total

1.  Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.

Authors:  Bruna Kochhann Menezes; Izabel Almeida Alves; Keli Jaqueline Staudt; Betina Montanari Beltrame; Letícia Venz; Lessandra Michelin; Bibiana Verlindo Araujo; Leandro Tasso
Journal:  Braz J Microbiol       Date:  2019-12-16       Impact factor: 2.476

Review 2.  Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Authors:  Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler
Journal:  Nat Rev Microbiol       Date:  2019-04       Impact factor: 60.633

3.  Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.

Authors:  Tilman Lingscheid; Wolfgang Poeppl; Dominik Bernitzky; Luzia Veletzky; Manuel Kussmann; Roberto Plasenzotti; Heinz Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Authors:  Sujata M Bhavnani; Paul G Ambrose; Jeffrey P Hammel; Christopher M Rubino; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

5.  Study on daptomycin use and implementation of an antimicrobial stewardship program.

Authors:  Camille Castel; Arnaud de La Blanchardière; Jocelyn Michon; Vincent Cattoir; Guillaume Saint-Lorant
Journal:  Int J Clin Pharm       Date:  2016-03-07

6.  Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus.

Authors:  Claudio Diaz-Ledezma; Carlos A Higuera; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2013-02-26       Impact factor: 4.176

7.  High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.

Authors:  Jordan R Smith; Kimberly C Claeys; Katie E Barber; Michael J Rybak
Journal:  Curr Infect Dis Rep       Date:  2014-10       Impact factor: 3.725

Review 8.  New developments and future challenges in prevention, diagnosis, and treatment of prosthetic joint infection.

Authors:  Benjamin F Ricciardi; Gowrishankar Muthukrishnan; Elysia A Masters; Nathan Kaplan; John L Daiss; Edward M Schwarz
Journal:  J Orthop Res       Date:  2020-01-31       Impact factor: 3.494

Review 9.  Prosthetic joint infection.

Authors:  Aaron J Tande; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

10.  The safety and efficacy of high-dose daptomycin combined with rifampicin for the treatment of Gram-positive osteoarticular infections.

Authors:  Kheeldass Jugun; Pierre Vaudaux; Jorge Garbino; Leonardo Pagani; Pierre Hoffmeyer; Daniel Lew; Ilker Uçkay
Journal:  Int Orthop       Date:  2013-03-22       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.